Beta3-adrenoreceptor agonist mirabegron – a potential antiobesity drug?

Click to increase image sizeClick to decrease image size

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This paper was supported by the Czech Ministry of Health [project number 00023761, Institute of Endocrinology, Prague, Czech Republic].